Gloria Iacoboni

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser et al. · New England Journal of Medicine · 2022 · 676 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni et al. · Journal of Clinical Oncology · 2021 · 413 citations · Full text

Life Sciences, Immunology, Oncology +17

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni et al. · Journal for ImmunoTherapy of Cancer · 2022 · 191 citations · Full text

Medicine, Hematology, Immunology +17

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Nicolas Gazeau, Emily C. Liang, Qian Wu et al. · Transplantation and Cellular Therapy · 2023 · 135 citations · Full text

Life Sciences, Immunology, Neurology +12

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Gloria Iacoboni, Guillermo Villacampa, Núria Martínez‐Cibrián et al. · Cancer Medicine · 2021 · 134 citations · Full text

Medicine, Hematology, Oncology +14